Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 143, Issue 2, Pages 275-291Publisher
SPRINGER
DOI: 10.1007/s00432-016-2278-1
Keywords
Adrenergic system; Catecholamines; Cancer; Proliferation; beta-Blockers
Categories
Ask authors/readers for more resources
In this review, we aimed to present and discuss the available preclinical and epidemiological evidences regarding the modulation of cancer cell proliferation by beta-adrenoceptors (beta-AR), with a specific focus on the putative effects of beta-blockers according to their pharmacological properties. A comprehensive review of the published literature was conducted, and the evidences concerning the involvement of beta-AR in cancer as well as the possible role of beta-blockers were selected and discussed. The majority of reviewed studies show that: (1) All the cancer types express both beta 1- and beta 2-AR, with the exception of neuroblastoma only seeming to express beta 2-AR; (2) adrenergic agonists are able to increase proliferation of several types of cancers; (3) the proliferative effect seems to be mediated by both beta 1- and beta 2-AR; (4) binding to beta-AR results in a cAMP transient flux which activates two major downstream effector systems: protein kinase A and EPAC and (5) beta-blockers might be putative adjuvants for cancer treatment. Overall, the reviewed studies show strong evidences that beta-AR activation, through several intracellular mechanisms, modulate tumor cell proliferation suggesting beta-blockers can be a feasible therapeutic approach to antagonize beta-adrenergic response or have a protective effect per se. This review highlight the need for intensifying the research not only on the molecular mechanisms underlying the beta-adrenergic influence in cancer, but also on the implications of biased agonism of beta-blockers as potential antitumor agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available